Background: Older patients are often underrepresented in clinical trials investigating the treatment of coronary drug-eluting stent (DES) restenosis, but outcome data is urgently needed in an ageing society. Thus, the aim of this observational, retrospective study was to close this lack of evidence.
Methods: Between January 2007 and February 2021, 3511 patients with 5497 in-stent restenosis (ISR) lesions were treated at two large-volume centers in Munich, Germany. We compared the rates of cardiac death, myocardial infarction (MI) and repeat revascularization in 1105 patients (31.5 %) older than 75 years with 2406 patients (68.5 %) younger than 75 years. Survival was analyzed using the Kaplan-Meier method. Differences between the groups were tested with the log-rank test. Conventional multivariable analysis with adjustment for relevant variables was performed.
Results: Older patients were more frequently female (30.1 % vs. 17.9 %, p < 0.001) and presented less frequently with stable angina (67.8 % vs. 72.0 %, p < 0.001). After 10 years, the rates of cardiac death were 56.8 % in older patients and 27.4 % in younger patients (HR, 2.45 [95 % CI, 2.09-2.88], p < 0.001). Accounting for the risk of death, no difference was found regarding the rates of MI while target lesion revascularization (TLR) occurred less frequently in older patients (24.2 % vs. 33.7 %; HR, 0.77 [95 % CI, 0.66-0.89], p < 0.001).
Conclusions: In the long-term, rates of cardiac death after percutaneous coronary intervention of DES-ISR were higher and TLR rates were lower in patients older than 75 years. There was no difference in the rates of MI.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.ijcard.2025.133109 | DOI Listing |
JACC Cardiovasc Interv
February 2025
Interventional Cardiology, ZAS Cardiovascular Center Middelheim, Antwerp, Belgium.
Background: The sirolimus-eluting bioadaptor is a novel coronary implant that unlocks, separates, and maintains dynamic support of the vessel at the lesion site 6 months after percutaneous coronary intervention when the polymer coating covering the helical strands resorbs. This enables the bioadaptor to maintain the established flow lumen and to restore hemodynamic modulation of the artery, including cyclic pulsatility, vasomotion, and adaptive remodeling.
Objectives: The purpose of this study was to report the first randomized clinical evidence of the DynamX bioadaptor implant through 2 years compared with the Resolute Onyx contemporary drug-eluting stent.
Int J Cardiol
March 2025
Deutsches Herzzentrum München, Department of Cardiology, Universitätsklinikum der Technischen Universität München, Munich, Germany; DZHK (German Centre for Cardiovascular Research), Partner site Munich Heart Alliance, Munich, Germany. Electronic address:
Background: Older patients are often underrepresented in clinical trials investigating the treatment of coronary drug-eluting stent (DES) restenosis, but outcome data is urgently needed in an ageing society. Thus, the aim of this observational, retrospective study was to close this lack of evidence.
Methods: Between January 2007 and February 2021, 3511 patients with 5497 in-stent restenosis (ISR) lesions were treated at two large-volume centers in Munich, Germany.
Kaohsiung J Med Sci
March 2025
Department of Cardiology II, General Hospital of Fuxin Mining Industry Group of Liaoning Health Industry Group, Fuxin, Liaoning, P. R. China.
This study aims to investigate the relationship between serum secreted frizzled-related protein 5 (SFRP5), apolipoprotein A-I (ApoA-I), high-density lipoprotein 3-cholesterol (HDL3-C) and in-stent restenosis (ISR) after percutaneous coronary intervention (PCI) in acute myocardial infarction (AMI) and their combined predictive value. The clinical data of 128 AMI patients who underwent PCI in our hospital from July 2020 to July 2023 were retrospectively analyzed. After 12 months of follow-up, the patients were divided into the ISR group (24 cases) and the non-ISR group (104 cases) according to the results of coronary angiography.
View Article and Find Full Text PDFCardiol Res
April 2025
Department of Non-Surgical Clinical Sciences, Faculty of Medicine, Wroclaw University of Science and Technology (WUST), Wroclaw, Poland.
Background: Drug-eluting balloons, surface-coated with antiproliferative agents such as sirolimus or paclitaxel, have emerged as an alternative therapeutic option for coronary stenosis. This study evaluated safety and effectiveness of the MOZEC sirolimus-eluting percutaneous transluminal coronary angioplasty (PTCA) balloon dilation catheter (Meril Life Sciences Pvt. Ltd.
View Article and Find Full Text PDFJ Invasive Cardiol
March 2025
Northwell Health at Lenox Hill Hospital, New York, New York; Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Uniondale, New York.
Objectives: This study aimed to evaluate the utilization and clinical outcomes of coronary intravascular brachytherapy (IVBT) as a treatment modality for multilayer in-stent restenosis (ISR).
Methods: This multicenter study retrospectively analyzed 101 patients who presented for percutaneous intervention of recurrent drug-eluting stent ISR using IVBT from 2019 to 2023. The primary outcome assessed was target lesion revascularization (TLR) at 1 year.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!